First batch of DRDO's 2DG drug for COVID treatment likely to be launched next week
The first batch of drug 2-Deoxy-D-Glucose, developed by the Defence Research and Development Organisation (DRDO), is expected to be launched next week for the COVID patients.
The drug recently got approval for emergency use by the Drugs Controller General of India (DCGI). The drug will only be provided to the COVID patients by the hospitals.
According to AIR news, DRDO sources said that larger quantities of 2DG drug will be produced from the beginning of the next month.
The drug 2-Deoxy-D-Glucose comes in powder form in a sachet, which needs to be taken orally by dissolving it in water. It accumulates in the virus-infected cells and prevents virus growth by stopping viral synthesis and energy production. Its selective accumulation in virally infected cells makes this drug unique.
An anti-COVID-19 therapeutic application of the drug 2-deoxy-D-glucose (2-DG) has been developed by INMAS, a lab of DRDO, in collaboration with Dr Reddy’s Laboratories, Hyderabad. The drug will help in faster recovery of Covid-19 patients. https://t.co/HBKdAnZCCP pic.twitter.com/8D6TDdcoI7— DRDO (@DRDO_India) May 8, 2021
Results of clinical trials have shown that this molecule helps in the faster recovery of hospitalised patients and reduces supplemental oxygen dependence.
(Edited by Ibankyntiew Mawrie)
TNT-The Northeast Today is now on WhatsApp. CLICK HERE to receive more updates on your phone.